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ABSTRACT 
 
Loads of reactive oxygen species (ROS), including superoxide anion and nitric oxide, that 
overburden antioxidant systems induce oxidative stress in the body. Major cellular targets 
of ROS are membrane lipids, proteins, nucleic acids, and carbohydrates. Circumstantial 
evidence suggests that ROS play a crucial role in the initiation and progression of various 
diseases in children and adolescents. The involvement of ROS and oxidative stress in 
pediatric diseases is an important concern, but oxidative stress status in young subjects and 
appropriate methods for its measurement remain to be defined. Recently, specific 
biomarkers for oxidative damage and antioxidant defense have been introduced into the 
field of pediatric medicine. This review is intended to provide an overview of clinical 
applications of oxidative stress biomarkers in the field of pediatric medicine. First, this 
review presents the biochemistry and pathophysiology of ROS and antioxidant defense 
systems. Second, it presents a list of clinically applicable biomarkers, along with pediatric 
diseases in which enhanced oxidative stress might be involved. The discussion emphasizes 
that several reliable biomarkers are easily measurable using enzyme-linked immunosorbent 
assay. Third, this review presents age-related reference normal ranges of oxidative stress 
biomarkers, including urinary acrolein-lysine, 8-hydroxy-2’-deoxyguanosine, nitrite/nitrate, 
and pentosidine, and the changes of the parameters in several clinical conditions, including 
atopic dermatitis and diabetes mellitus. New and interesting data on oxidative stress and 
antioxidant defenses in neonatal biology are also presented. Fourth, this review discusses 
the ever-accumulating body of data linking oxidative stress to disturbances of the nitric 
oxide system and vascular endothelial activation/dysfunction. Finally, this review describes 
the reported clinical trials that have evaluated the efficacy of antioxidants for 
oxidative-stress related diseases. Suggestions are advanced for the direction of future trials 
using antioxidant therapies. Repeated measurement of appropriate parameters will enable 
us to discern the pathophysiological patterns of pediatric diseases and guide our therapies 
appropriately. 
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(1) INTRODUCTION - REACTIVE OXYGEN SPECIES AND OXIDATIVE STRESS 
 
Free radicals and reactive oxygen species 
 
Free radicals are defined as “any chemical species capable of independent existence that 
contains one or more unpaired electrons”. Oxygen (O2) and nitrogen (N2) together 
constitute over 98% of the air we breathe. All animals require O2 for efficient production of 
energy. By definition, O2 itself is a free radical. Reactive oxygen species (ROS) are free 
radicals that are associated with the oxygen atom (O) or their equivalents and have stronger 
reactivity with other molecules, rather than with O2 [1, 2]. 
 
Typically, ROS are generated as byproducts of cellular metabolism and ionizing radiation, 
usually indicating the following four species: superoxide anion (O2-), hydrogen peroxide 
(H2O2), hydroxyl radical (OH), and singlet oxygen (1O2). Of those, H2O2 and 1O2 are not 
free radicals by definition, but these species behave similarly to free radicals. Reactivity of 
either O2- or H2O2 by itself with other molecules is rather low, but in the presence of trace 
amounts of a transition metal, they are converted to OH via the Fenton or Haber-Weiss 
reaction. 
 
Other biologically important free radicals or their equivalents exist: lipid hydroperoxide 
(ROOH), lipid peroxyl radical (ROO), and lipid alkoxyl radical (RO), which are associated 
with membrane lipids; nitric oxide (NO), nitrogen dioxide (NO2) and peroxynitrite 
(ONOO-), which are reactive nitrogen species; and thiyl radical (RS), which has an 
unpaired electron on the sulfur atom. It should be noted here that one major mechanism by 
which excess NO can injure tissues is by its rapid reaction with O2- to give ONOO-. 
Sections (2) and (8) of this paper include descriptions of the biological chemistry and 
pathophysiology of the NO system. 
 
Antioxidant systems 
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The ROS serve in cell signaling as messenger molecules of the autocrine and paracrine 
systems and in host defense (biocidal effects against microbial and tumor cells) [1, 2]. 
However, their excess production might engender tissue injury and inflammation. Any 
excess production of ROS is strictly limited through electron transfer, enzymatic removal, 
scavenging, and by keeping transition metals tightly sequestered using a well-managed and 
efficient endogenous antioxidant defense mechanism. Under normal physiological 
conditions, the balance between production and elimination of ROS is maintained by 
enzymes and antioxidants. 
 
Biologically active enzymes and antioxidants are categorized into three groups: enzymes, 
such as super oxide dismutase (SOD), catalase, glutathione peroxidase, glutathione 
reductase, glutathione-S-transferase (GST), thioredoxin reductase, and heme oxygenase 
(HO); proteins, which include albumin, ferritin, transferrin, lactoferrin, ceruloplasmin, and 
thioredoxin (TRX); and low molecular weight molecules, including bilirubin, tocopherols, 
carotenoids, ubiquinol/ubiquinone, ascorbate, glutathione, cysteine, and urate. Any 
imbalance between oxidant and antioxidant activities results in a state of 
oxidant-antioxidant disequilibrium. Any excess of the former creates a condition of 
“oxidative stress”. 
 
It is now well established that ROS and oxidative stress are involved in various 
pathological phenomena including aging, atherosclerosis, hypertension, renal failure, 
immune alterations, neurodegeneration, reperfusion injury, radiation damage, 
carcinogenesis, and many other inflammatory and degenerative conditions [1, 2]. 
 
(2) NITRIC OXIDE SYSTEM AND OXIDATIVE STRESS 
 
Enzymatic and nonenzymatic production of nitric oxide 
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Oxidative stress and NO formation are inextricably intertwined. For that reason, this 
discussion also addresses the L-arginine-NO system in the body. An uncharged, diatomic, 
free radical gas, NO is diffusible and its biological effects are determined by its chemical 
reactivity [1]. It is produced enzymatically by nitric oxide synthases (NOSs; 130-160 kDa 
molecular weight) from L-arginine and molecular oxygen using NADPH as an electron 
donor, and using heme, FAD, FMN and tetrahydrobiopterin (BH4) as cofactors through a 
reaction that consumes five electrons. 
 
In mammals, NOSs exist in three isoforms, which differ in the way their activity is 
controlled. They are neuronal (NOS1), inducible (NOS2) and endothelial (NOS3). Of them, 
NOS1 and NOS2 are soluble, whereas NOS3 is membrane bound, with its myristoylated 
N-terminal. The NOS1 and NOS3 are constitutively present in various types of cells and 
are activated by transient increases in intracellular calcium. Upon demand by a signal 
molecule, NO is synthesized in low concentrations by constitutive NOSs. It binds to heme 
iron of soluble guanylate cyclase to yield the second messenger cGMP, which in turn 
modulates an array of mediators, including ion channels, phosphodiesterases and protein 
kinases, which thereby decrease intracellular calcium concentrations, and allow smooth 
muscle relaxation while inhibiting platelet aggregation. The third isoform, NOS2, is 
induced in response to inflammatory and immunological stimuli in myriad cells, including 
vascular endothelial cells, smooth muscle cells and activated immune cells. That isoform 
generates NO independently of intracellular calcium levels. The output of NO from NOS2 
is about 1,000 times that of the other constitutive isoforms. 
 
Not only enzymatically, NO can also be synthesized nonenzymatically from nitrite (NO2-) 
at low pH under reducing conditions. Nonenzymatic NO production might play a role in 
similar biological events as when NO is generated by NOS enzymes, in the stomach, on the 
skin surface, in the ischemic heart, and in infected nitrite-containing urine. Nitrite is now 
being recognized as a “hypoxic buffer” that potentially contributes to regulation of hypoxic 
vasodilation and to the modulation of ischemia-reperfusion tissue injury and infarction [3, 
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4]. 
 
Formation of peroxynitrite 
 
A free radical, NO reacts with O2- at nearly diffusion-controlled rates (6.7 × 109 M-1s-1) to 
give ONOO- [1]. This rate is three times higher than that of the reaction of O2- with SOD (2 
× 109 M-1s-1). For that reason, NO can compete with SOD for reaction with O2- when 
produced in concentrations that approach those of SOD. Normal physiological 
concentrations of NO and O2- are much lower than those of SOD. Therefore, little ONOO- 
is formed under normal conditions. Pathological situations involving simultaneous 
increases in NO and O2-, especially those occurring in regions of low SOD activity, would 
markedly increase the formation of ONOO-, which is a potent biological oxidant. The 
interaction between NO and O2- might represent a major pathway for NO toxicity, as well 
as an inactivation route for NO. 
 
(3) BIOMARKERS FOR OXIDATIVE STRESS 
 
Categorization of oxidative stress biomarkers 
 
All biomolecules can be damaged by ROS (including ONOO-). Oxidative damage to lipids, 
proteins, nucleic acids, and carbohydrates can be deleterious and concomitant [1, 2]. The 
primary cellular target of oxidative stress depends on the cell type, the nature of the stress 
imposed, the site of generation, the proximity of ROS to a specific target, and the stress 
severity. The half-lives of ROS are usually short. Therefore, special techniques are 
necessary to detect ROS in vivo. So-called “oxidative stress biomarkers” can not only 
determine the extent of oxidative injury, but also indicate the source of the oxidant [5-8]. 
Oxidative stress biomarkers are important for predicting the consequences of oxidation and 
for providing a basis for designing appropriate interventions to prevent or alleviate injury. 
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Briefly, oxidative stress biomarkers are separable into two categories: (a) formation of 
modified molecules by ROS; and (b) consumption or induction of enzymes or antioxidants 
[2] (Table 1). Measurement of these biomarkers in body fluids (e.g., blood, urine, 
cerebrospinal fluid, bronchoalveolar lavage fluid) or breath condensate [6] enables repeated 
monitoring of the oxidative stress status in vivo, which is not possible with invasive tests. It 
might be appropriate to evaluate levels of oxidative stress markers in addition to routine 
laboratory assessments. Detection of ROS generation in human live cells might be possible 
through the use of fluorescent probes [2, 9]. Unfortunately, at present, it is not easy to apply 
this method to clinical practice. 
 
The first category (a) includes molecules that are generated in a reaction with ROS. 
Molecules are subjected to either scission, cross-linking or covalent modification in these 
reactions. Accordingly, the amount of these molecules is increased when ROS are 
generated. Some are rapidly removed or repaired, but others remain in intracellular or 
extracellular compartments for a long time. Major targets of ROS in the molecular 
components of the cells are membrane lipids, proteins, nucleic acids, and carbohydrates. 
These markers are often measurable using stable adducts that are produced in vivo as a 
result of oxidative processes. Clinically applicable biomarkers include 
malondialdehyde-lysine, 4-hydroxy-2-nonenal-lysine, acrolein-lysine (markers of lipid 
peroxidation), 8-hydroxy-2’-deoxyguanosine (8-OHdG) (a marker of oxidative DNA 
damage), carboxymethyl-lysine, pentosidine (markers of glyco-oxidation), nitrotyrosine, 
nitrite/nitrate (markers of nitro-oxidation), bilirubin oxidative metabolites (BOM) (a marker 
of HO activity), and so forth (Table 1). 
 
Here, brief descriptions of these markers are useful. Acrolein-lysine is a sensitive marker of 
lipid peroxidation and oxidative protein damage [5, 8]. Among the base modifications 
induced by ROS, 8-OHdG is an abundant oxidative DNA product. Many studies have 
measured 8-OHdG as a sensitive marker of oxidative DNA damage [2, 8]. Oxidative stress 
is usually involved in advanced glycation end product (AGE) formation; AGEs induce 
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oxidative stress. Pentosidine is a major marker of oxidative glycation [7, 8]. Uniquely 
among ROS, NO might act as a prooxidant as well as an antioxidant, depending on the 
degree, site, and timing of its generation [1]. Nitrite/nitrate is used as a marker for 
endogenous NO formation [8].  
 
A major antioxidant enzyme, heme oxygenase (HO), catalyzes the rate-limiting step in 
heme degradation [10, 11]. Two isoforms, HO-1 (inducible) and HO-2 (constitutive), are 
classified as HO. The first, HO-1, is induced in various cells by various stimuli that 
provoke oxidative stress, including heme, heat shock, proinflammatory cytokines, and 
toxins. The primary product of HO is bilirubin. Bilirubin functions as a potent antioxidant 
under physiological and pathophysiological conditions. Bilirubin reacts with ROS and, 
subsequently, becomes oxidized. Hence, BOM, rather than bilirubin per se, might be a good 
marker for evaluating the antioxidant activity of bilirubin under oxidative stress. In other 
words, elevated levels of BOM reflect up-regulation of HO under stressful conditions. The 
BOM concentrations in body fluids can be determined easily using a newly developed 
ELISA system (Biopyrrin ELISA; Dojindo Laboratories, Kumamoto, Japan) [12-14].  
 
The second category (b) consists of antioxidant enzymes and molecules that are associated 
with ROS metabolism. In most cases, these molecules are destroyed or modified and 
exhibit decreased activity or quantity after exposure to ROS. Conversely, they often show 
an overshooting response for a matter of hours, days, or weeks. A variety of antioxidant 
enzymes, proteins, and low-molecular-weight molecules can be listed (Table 1). 
 
Oxidative stress biomarkers in pediatric medicine 
 
This review outlines recent achievements of oxidative stress marker determination in 
pediatric medicine. It is important to examine the combination of oxidative stress 
biomarkers constructively to confirm the participation of oxidative stress in certain 
pathological conditions. This review includes our recent achievements in this particular 
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field and emphasizes the emerging applicability of enzyme-linked immunosorbent assay 
(ELISA) for investigating oxidative stress status in young people. Reference normal ranges 
of oxidative stress biomarkers and abnormal changes of the biomarkers in certain 
pathologies, e.g., atopic dermatitis and diabetes mellitus, are described. New and interesting 
data on oxidative stress and antioxidant defenses in neonatal biology are presented. 
 
(4) POSSIBLE INVOLVEMENT OF OXIDATIVE STRESS IN PEDIATRIC DISEASES 
 
Determination of oxidative stress biomarkers in pediatric diseases 
 
Numerous diseases of children and adolescents appear to be linked to oxidative damage 
attributable to ROS in their pathogenesis and progression (Table 2) [15-115]. Oxidative 
stress might also contribute to tissue damage induced by certain drugs (e.g., analgesics, 
anticancer drugs, immunosuppressive drugs) [116-121]. In most previous studies, oxidative 
stress biomarkers were determined in samples of blood (i.e., serum, plasma, erythrocytes, 
granulocytes, or lymphocytes) or urine. In several studies, the parameters were measured 
using other body fluids (e.g., cerebrospinal fluid [17, 34, 36], bronchoalveolar lavage fluid 
[67, 115], joint fluid [85], nasal lavage fluid [74], middle-ear fluid [87]), tissues [24, 31, 32, 
56, 60, 62, 78, 82, 87, 105], or exhaled breath [40, 61, 65], either alone or in combination 
with samples of blood or urine. 
 
Previous studies measured oxidative stress biomarkers using analytic chemistry techniques, 
including high-performance liquid chromatography and gas chromatography-mass 
spectrometry. Recently, specific monoclonal antibodies have been developed and ELISA 
systems constructed for various oxidative stress biomarkers [8]. Onerous pretreatments and 
expensive apparatus are virtually obviated by ELISA; it is a labor-saving, cost-saving 
method that provides results quickly. Examination using a few sample aliquots is possible. 
Its reproducibility is excellent. This technique is demonstrated as suitable for use in clinical 
medicine and has spread quickly to analyses of clinical samples. Analyses of oxidative 
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stress in various pediatric pathologies are now performed predominantly using 
high-throughput ELISA methods [17, 21, 22, 27, 29, 34, 36, 50, 52, 58, 63, 65, 72, 86, 96, 
97, 99, 108, 110, 114]. 
 
Importance of oxidative stress research in pediatric medicine 
 
Oxidative tissue injury from pathological conditions might have more serious consequences 
in young people (especially children) than in older people because of the need for 
subsequent tissue growth to match somatic growth and because survival is longer in young 
people than in older people. Primary and secondary prevention of oxidative damage might 
therefore be important, especially in young people. Furthermore, the use of antioxidants has 
presented new therapeutic perspectives for diseases that are related to enhanced oxidative 
stress. 
 
Previous studies of oxidative stress [15–115], although bringing forth interesting results, 
had limited sample sizes and might not have convincing evidence to prove clear causality 
between oxidative stress and disease conditions. Other factors might be eminently 
responsible for disease pathogenesis and progression. It remains difficult to determine the 
extent to which oxidative stress is a contributory pathogenic mechanism in the etiology of 
pediatric pathologies. Perhaps it is the right time to pursue intensive research into oxidative 
stress in pediatric patients with a wide range of diseases. 
 
(5) REFERENCE NORMAL VALUES OF OXIDATIVE STRESS BIOMARKERS 
 
Normal reference ranges in the literature 
 
Investigation of the role of oxidative stress in pediatric diseases requires information about 
the oxidative stress status of young populations. It will be possible to evaluate the 
contribution of oxidative stress to various pediatric diseases and establish better approaches 
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for each disease when we know normal levels of oxidative stress in children and 
adolescents. However, only a few reports describe oxidative stress status in healthy children 
and adolescents. The studied subjects in those studies are few or fit a narrow age range 
[122-126]. In most studies, blood was collected from subjects for analyses of the following: 
reduced/oxidized glutathione, glutathione peroxidase and glutathione reductase activities, 
selenium [123]; antioxidant vitamins (including α-tocopherol, γ-tocopherol, α-carotene, and 
β-carotene) [124]; ubiquinol/ubiquinone [125]; and “thiobarbituric acid reactive 
substances” and SOD and catalase activities [126]. Schock et al. [122] reported levels of 
antioxidant vitamins (α-tocopherol, ascorbate), urate, and protein carbonyls in 
bronchoalveolar lavage fluid of 83 healthy children (age range, 1.6-12.0 years). 
 
Kauffman et al. [124] determined urinary levels of F2-isoprostane in 342 healthy children 
who were less than 7 years old. To our knowledge, this is the only study that evaluates 
oxidative stress in a large population of healthy children using urine samples. Other studies 
used small groups of healthy children and adolescents as age-matched controls, rather than 
as the focus of those studies [16, 18, 21, 27, 44, 50, 58, 63, 72, 86, 110, 114]. Consequently, 
normal values for urinary biomarkers of oxidative stress in young people are lacking. 
 
Urine collection is simple, quick, comfortable, non-invasive, and therefore particularly easy 
to perform in children. Collection of spot urine samples is much more feasible than 24-h 
collection and standardization by creatinine (Cr) excretion corrects for variation in water 
intake. The determined urinary levels are thought to reflect the stable condition of the 
subjects if early-morning urine samples are analyzed. Therefore, urine is inferred to be an 
appropriate biological fluid sample for evaluating changes of oxidative stress status in 
various pediatric pathologies. 
 
Our data on normal reference ranges of oxidative stress biomarkers 
 
Our data for evaluation of oxidative stress levels in healthy young subjects were of 100 
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healthy Japanese subjects (50 males and 50 females) of a broad age range (age range, 
1.5-21.0 years). Early-morning void urine samples were obtained for analyses of 
biomarkers reflecting oxidative damage to lipids, DNA, and carbohydrates. Acrolein-lysine 
and 8-OHdG were determined using competitive ELISA kits (ACR-Lysine Adduct ELISA; 
NOF Corp., Tokyo, Japan [34, 58, 63, 86, 114], and 8-OHdG Check; Institute for the 
Control of Aging, Shizuoka, Japan [17, 21, 58, 63, 86, 96, 108, 114], respectively). 
Nitrite/nitrate was measured using colorimetric, non-enzymatic assay (Bioxytech Nitric 
Oxide Non-Enzymatic Assay; Oxis International Inc., Portland, OR, USA) [21, 34, 58, 86, 
114]. Pentosidine and pyrraline were determined using high-performance liquid 
chromatography with fluorometric detection, as detailed previously [63, 77, 127]. 
Pentosidine is a major marker of oxidative glycation, whereas pyrraline is a marker of pure 
glycation [6, 8, 127]. 
 
The levels of urinary acrolein-lysine, 8-OHdG, nitrite/nitrate and pentosidine showed 
significant inverse correlations with age: r = -0.54, -0.66, -0.43, -0.56, respectively, by 
linear regression analysis; p < 0.001. More specifically, these urinary biomarkers were 
highest in the youngest subjects and decreased with age to reach constant levels by early 
adolescence (Figs. 1 and 2). However, the levels of pyrraline did not correlate significantly 
with age in the subjects (r = -0.19). No significant differences were found between males 
and females for any oxidative stress parameters. 
 
Higher levels of oxidative stress biomarkers in young people 
 
The physiological meaning and mechanisms for the high levels of urinary oxidative stress 
biomarkers in younger subjects are not clarified yet. It is noteworthy that urinary excretion 
of repair products of oxidative DNA damage (e.g., 8-oxo-7,8-dihydroguanine, 8-OHdG) is 
several times higher in rapidly growing animals (e.g., mice, rats) than in humans [128]. A 
high metabolic rate might be responsible for the increased everyday oxidative DNA insults 
in rapidly growing animals. Younger people, who are growing rapidly, have a higher 
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metabolic rate than older people. That higher metabolic rate requires a higher level of 
mitochondrial respiration and subsequent higher production of ROS, which might be 
responsible for the high levels of urinary oxidative stress biomarkers in younger people. 
This interpretation of our results is supported by the lack of age-related changes of a 
non-oxidative glycation marker, pyrraline. It should be emphasized that, under normal 
physiological conditions, younger people (especially children) are likely to be exposed to 
higher concentrations of ROS and NO than older people. 
 
We recognize that our study and its implications are limited by the modest size and 
cross-sectional design of the study. Nevertheless, this study’s findings support continued 
investigation into age-related changes in urinary oxidative stress biomarkers and their 
physiological significance with a higher number of subjects and with other techniques to 
measure oxidative stress. 
 
Kauffman et al. [124] studied healthy children and found that urinary F2-isoprostane levels 
were highest in infancy and decreased until 7 years old. The ratio of reduced glutathione to 
oxidized glutathione and that of ubiquinol to ubiquinone were reported to be higher in 
children than in adults [123, 125]. Glutathione and ubiquinol might function as protective 
antioxidants in young people. These results probably represent physiological changes 
associated with normal aging, but a better understanding of oxidative processes in children 
and adolescents is necessary. We should devote attention to the age of the subjects when 
interpreting data of urinary oxidative stress biomarkers in young people, e.g., 
acrolein-lysine, 8-OHdG, nitrite/nitrate and pentosidine. We should also evaluate whether 
potential changes in oxidative stress status are attributable to disease progression or merely 
an effect of aging per se. 
 
(6) CHANGES OF OXIDATIVE STRESS BIOMARKERS IN PEDIATRIC DISEASES 
 
Panel of oxidative stress biomarkers 
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Oxidative damage might take place in a selective manner. For instance, lipid peroxidation 
and oxidative DNA damage are not always accompanied by overproduction of NO. The 
detection of more than one marker for oxidative stress is an important key because a single 
marker might give misleading results. It might also be crucial to determine which particular 
markers, alone or in combination with others, can serve as a true indicator of the 
contribution of oxidative stress to a disease, thereby allowing the success (or failure) of the 
treatment to be monitored. The following are good examples. 
 
Atopic dermatitis 
 
Atopic dermatitis (AD) is a chronic or chronically relapsing inflammatory skin disease that 
is characterized by typically distributed eczematous skin lesions with accompanying 
lichenification, pruritic excoriations, dry skin, and susceptibility to skin infections [129]. 
Although the pathophysiological mechanisms of AD are not completely clear, inflammatory 
cell activation and dysregulated cytokine production appear to play a critical role in AD 
pathogenesis. In this setting, alterations in the flux of ROS can exert profound influences 
on the pathophysiology. 
 
We examined the involvement of oxidative stress and antioxidant defense in children with 
acute exacerbation of AD [58]. We studied 13 children who were hospitalized for acute 
exacerbation of AD with purulent skin infection by Staphylococcus aureus and 28 
age-matched healthy controls. Urine samples obtained from the patients on admission, on 
the 2nd and 7th-9th hospital days and from control subjects were assayed for 
acrolein-lysine, 8-OHdG, BOM (using ELISA methods) and nitrite/nitrate (using 
colorimetry). Of these, urinary levels of acrolein-lysine, 8-OHdG and BOM, but not 
nitrite/nitrate, were significantly higher in AD children on admission than in control 
subjects. Response to treatment (with systemic antibiotics and topical antiseptics and 
corticosteroids) was associated with significant decreases in levels of acrolein-lysine and 
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8-OHdG. Urinary BOM remained almost constant and was significantly higher in AD 
children during hospitalization. 
 
These results do not indicate that endogenous NO synthesis in children with acute 
exacerbation of AD is enhanced in comparison to that in control subjects. As described in 
Section (3), up-regulation of HO and the consequent increased production of bilirubin 
constitute physiological responses to oxidative stress. This is probably the major 
mechanism of increased BOM excretion in children with acute exacerbation of AD. 
 
In another study, we found significantly higher urinary levels of 8-OHdG and significantly 
lower urinary levels of nitrite/nitrate in children having chronic AD without recent flare-up 
than those in age-matched control subjects [21]. These findings imply that the activity of 
constitutive and/or inducible NOSs is limited in patients with chronic AD. Reduced 
production of NO might augment oxidative stress and exaggerate skin lesions caused by 
chronic AD [130]. Section (8) also presents discussion of this topic. 
 
Diabetes mellitus 
 
Recent studies have indicated that hyperglycemia-induced overproduction of ROS and 
AGEs appears to be the first and main event in the activation of all pathways involved in 
the pathogenesis of vascular complications of diabetes mellitus [7, 131-133]. Augmented 
oxidative stress is accompanied by increased generation of NO and, consequently, 
formation of the strong oxidant ONOO- and by poly(ADP-ribose) polymerase activation, 
which in turn results in acute endothelial dysfunction and activation of inflammation in 
blood vessels of patients with diabetes. Therefore, the concentrations of oxidative stress 
biomarkers in blood or urine might serve well as a marker for later development of vascular 
complications in diabetes mellitus. 
 
Recently, we examined whether AGE production and oxidative stress were augmented in 
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young patients with type 1 diabetes at early clinical stages of the disease [63]. Urinary 
samples of 38 patients with type 1 diabetes and those of 60 age-matched healthy control 
subjects were assayed, using high-performance liquid chromatography, for AGEs, 
pentosidine and pyrraline. In addition, using ELISA methods, their samples were assayed 
for markers of oxidative stress, acrolein-lysine and 8-OHdG. Of these four markers, urinary 
levels of pentosidine, acrolein-lysine, and 8-OHdG, but not pyrraline, were significantly 
higher in diabetic patients than in control subjects. For the patient group, urinary 
pentosidine, acrolein-lysine and 8-OHdG, but not pyrraline, correlated significantly with 
urinary albumin excretion. These results indicate that, in the course of type 1 diabetes, 
accumulation of AGEs, whose formation is closely linked to oxidative stress, might start 
early along with renal microvasculopathy. 
 
(7) OXIDATIVE STRESS AND ANTIOXIDANT DEFENSES IN NEONATAL BIOLOGY 
 
Oxidative stress in fetal-neonatal transition 
 
It has been reported repeatedly that newborns are exposed to conditions of oxidative stress 
resulting from the change from a low oxygen pressure in utero (pO2 20-25 Torr) to a high 
oxygen pressure at birth (pO2 100 Torr) [134, 135]. The energy metabolism efficiency 
increases rapidly after birth because all aerobic organisms require oxygen for energy 
production and maintenance of cellular functions. Neonates must also withstand the 
associated generation of ROS, which can oxidize critical macromolecules. A protective 
mechanism develops during the third trimester of fetal life: increased antioxidant enzyme 
levels. This mechanism adequately prepares the neonate to endure higher concentrations of 
oxygen at birth. 
 
Nevertheless, sick neonates frequently suffer from oxidative injury because of their 
insufficient ability to protect themselves against oxidative insult [134, 135]. Increased 
oxidative stress plays an important role in the pathogenesis of many neonatal diseases, 
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including hypoxic ischemic encephalopathy, neonatal respiratory distress syndrome, 
chronic lung disease, retinopathy of prematurity, and necrotizing enterocolitis [92]. 
 
Determination of oxidative stress biomarkers in neonates 
 
We recently characterized oxidative stress status in one-month-old neonates using specific 
biomarkers, as measured using ELISA systems [86]. Results showed no significant 
difference in urinary acrolein-lysine and 8-OHdG between healthy term neonates and 
clinically stable preterm neonates. This finding suggests that stable preterm neonates, who 
require no supplemental oxygen, are not exposed to greater oxidation of lipids and DNA 
than healthy term neonates. In contrast, we noted significant elevations of both markers in 
sick preterm neonates requiring supplemental oxygen and mechanical ventilation in 
comparison to those of stable preterm neonates and healthy term neonates. In the sick 
preterm group, neonates developing active retinopathy showed significantly higher levels 
of acrolein-lysine than the other neonates without retinopathy did. 
 
We also measured urinary nitrite/nitrate concentrations in our subjects, but found no 
significant difference in urinary nitrite/nitrate among the above-mentioned three groups. 
These findings suggest that no close relationship exists between the degree of oxidative 
stress and endogenous NO production in neonates. 
 
Preeclampsia 
 
Preeclampsia is a disorder of human pregnancy and a leading cause of premature birth and 
fetal growth retardation [136]. In pregnancies that are complicated by preeclampsia, ROS 
production in the placenta increases in connection with inadequate antioxidant defense. 
Neonates born after preeclampsia have been exposed to more oxidative stress in utero than 
matched neonates [137]. 
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We recently found that pentosidine concentrations (as measured using high-performance 
liquid chromatography) in umbilical cord blood were significantly higher in neonates born 
after preeclampsia [77]. Our findings imply that oxidative stress and AGE formation are 
augmented in utero during preeclampsia. Enhanced oxidative stress is inferred to be a 
crucial factor in the progression of preeclampsia. 
 
Antioxidant biomarkers in neonates 
 
As described above, several urinary biomarkers for oxidative injury have been used to 
evaluate oxidative stress status in neonates. However, reliable biomarkers of antioxidant 
defense have never been reported in neonates. Some novel information related to such 
markers deserves introduction here. 
 
Fatty acid-binding proteins (FABPs) are a family of 14-15-kDa proteins. They are involved 
in the transport of free fatty acids from the plasma membrane to sites for oxidation (i.e., 
mitochondria, peroxisomes) and the nucleus for gene regulation [138]. Liver-type fatty 
acid-binding protein (L-FABP) is expressed in renal proximal tubules and engaged in free 
fatty acid metabolism [139]. Free fatty acids are loaded into the proximal tubules in 
oxidative conditions; thereby, they become cytotoxic. Transcription of the L-FABP gene is 
promoted by various kinds of stresses, including free fatty acids per se. For that reason, 
L-FABP is considered to serve as an antioxidant enzyme in the kidney. Recent clinical 
studies suggest that urinary excretion of L-FABP reflects oxidative stress on the proximal 
tubules and might be a useful biomarker for the progression of chronic kidney disease 
[139-142]. 
 
We measured urinary excretion of L-FABP (using the ELISA system developed by Sugaya, 
et al., L-FABP ELISA; CMIC Co. Ltd., Tokyo, Japan [139-142]) for the first time in 
preterm and term neonates [96]. Urinary levels of L-FABP in these neonates were 
remarkably higher than in healthy adults. Urinary L-FABP levels showed significant 
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positive correlation with those of 8-OHdG during the late neonatal period. These results 
attest to the expression of L-FABP in the neonatal kidney. They also suggest the potential 
effect of oxidative stress on the L-FABP expression. 
 
Detoxifying isoenzymes, GSTs, catalyze the conjugation of glutathione to a range of 
electrophilic compounds. They also exhibit a non-selenium-dependent glutathione 
peroxidase activity against organic hydroperoxides [143, 144]. The human renal distal 
tubules contain the π form of GST in great amounts. 
 
We measured urinary excretion of GST-π (using ELISA method, Urinary GST-π ELISA; 
Biotrin International, Dublin, Ireland) in preterm neonates for the first time [108]. Urinary 
levels of GST-π showed significantly positive correlation with urinary 8-OHdG at one and 
four weeks of age. Sick neonates treated with supplemental oxygen and mechanical 
ventilation showed significantly higher levels of GST-π as well as 8-OHdG than clinically 
stable neonates did at four weeks. These results indicate the potential effect of oxidative 
stress on the GST-π expression in the neonatal kidney. Considering the accumulated 
evidence described above, neonates appear to have two major antioxidant enzymes in the 
kidney (i.e., L-FABP and GST-π, respectively, in the proximal and distal tubules) through 
which many kinds of potentially oxidative endogenous and exogenous substances should be 
detoxified. 
 
Breast milk as a rich source of antioxidants 
 
Breast-feeding is associated with lower rates of several infantile diseases: respiratory illness, 
necrotizing enterocolitis, and sepsis. Breast milk consumption offers many advantages over 
consumption of infant milk formula, including provision of antioxidant protection to infants 
[145]. Breast milk contains various enzymatic and nonenzymatic antioxidants, including 
SOD, catalase, tocopherols, ascorbate, and lactoferrin. Shoji et al. [146] reported that 
urinary 8-OHdG was significantly lower in breast-fed infants than in formula-fed infants at 
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one month of age. This finding implies that oxidative DNA damage is lower in breast-fed 
infants. Therefore, it is conceivable that abundance of antioxidants in breast milk might 
help infants to eliminate ROS. 
 
We determined concentrations of nitrite/nitrate, ubiquinol/ubiquinone, tocopherols, 
β-carotene, and lycopene in human milk obtained from lactating women during the early 
postpartum period [147, 148]. The respective mean (SD) concentrations of these 
antioxidants were 479 (274) µmol/l, 352 (24), 10,760 (950), 153 (131), and 161 (196) 
ng/ml. Although the concentrations of the first three in Japanese standard infant milk 
formulas are comparable to those in human milk, concentrations of the latter two are 
remarkably lower in these formulas. 
 
A ubiquitous protein (12 kD), TRX has a three-dimensional structure containing two 
redox-active cysteine residues (-Cys-Gly-Pro-Cys-) [149]. The TRX system comprises 
several related molecules that interact through active-site cysteine residues. Against 
oxidative stresses of various sorts, TRX plays a potent cytoprotective role. Recently, we 
observed that breast milk concentrations of TRX (as measured using the ELISA system 
developed by Nakamura et al. [150], TRX ELISA Kit; Redox Bioscience Inc., Kyoto, 
Japan) during the early postpartum period (mean (SD) concentration, 268 (23) ng/ml) were 
seven to eight times higher than those in blood of lactating women [148]. In breasts of 
lactating women, TRX might be synthesized in high amounts. This abundance of TRX in 
human milk might be absorbed into the neonatal circulation and exert antioxidant functions 
in the neonate. 
 
Birth is a complex process that includes the abrupt challenge posed by oxidative stress. 
Neonates must adapt themselves rapidly and drastically to extrauterine life as the function 
of gas exchange is transferred from the placenta to the lungs [134, 135]. The above 
observations engender the contention that high levels of antioxidants in early breast milk 
provide a unique protective mechanism that allows the maintenance of redox balance 
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during the fetal-to-neonatal transition. 
 
(8) OXIDATIVE STRESS AND ENDOTHELIAL ACTIVATION/DYSFUNCTION 
 
Vascular endothelium 
 
The vascular endothelium, rather than being a mere barrier between intravascular and 
interstitial compartments, is a widely distributed organ that is responsible for regulation of 
hemodynamics, angiogenic vascular remodeling, and metabolic, synthetic, 
anti-inflammatory, and anti-thrombogenic processes. Understanding of the interrelationship 
of oxidative stress and endothelial activation/dysfunction [130, 151-154] will allow 
delineation of a rational therapeutic strategy in conditions that are associated with oxidative 
damage. Our experimental results on this topic, which are presented below, are illustrative. 
 
Endothelial activation experiments 
 
The adhesion molecules and chemokines expressed in endothelial cells play an important 
role in regulating recruitment of leukocytes to inflammation sites [151, 152]. Although 
enhanced expression of adhesion molecules and chemokines have been described for 
various allergic and immunologic diseases, including AD, bronchial asthma, and Kawasaki 
disease, the effects of antioxidants and NO on these inflammatory changes in human 
microvascular endothelial cells have not been clarified. 
 
First, we examined the effects of antioxidant, pyrrolidine dithiocarbamate (PDTC) and NO 
donor, spermine NONOate (Sper-NO) on adhesion molecule expression and nuclear factor 
κB (NF-κB) activation induced by tumor necrosis factor-α (TNF-α) in cultured human 
dermal microvascular endothelial cells (HDMEC) [155]. Treatment of cells with TNF-α 
significantly induced the surface and gene expression of E-selectin, intercellular adhesion 
molecule-1 and vascular cell adhesion molecule-1, and activation of NF-κB. The 
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up-regulation of these adhesion molecules and activation of NF-κB induced by TNF-α 
were decreased significantly by pretreatment with PDTC or Sper-NO. Next, we examined 
the effects of PDTC and Sper-NO on the secretion and gene expression of chemokines, 
interleukin-8, monocyte chemotactic protein-1, and regulated-upon-activation normal T-cell 
expressed and secreted [156]. Treatment with TNF-α significantly increased secretion and 
gene expression of these chemokines in cultured HDMEC; all were suppressed 
significantly by the two pretreatments mentioned above. These findings indicate that both 
expression of adhesion molecules and secretion of chemokines in HDMEC induced by 
TNF-α are inhibited significantly by pretreatment with PDTC or Sper-NO, possibly in part 
through blockage of NF-κB activation. 
 
Our investigations also showed that both expression of adhesion molecules and secretion of 
chemokines in human pulmonary microvascular endothelial cells induced by TNF-α were 
inhibited significantly by pretreatment with PDTC or Sper-NO, possibly via blocking of 
redox-regulated NF-κB activation [157, 158]. These results are consistent with findings of 
experiments using HDMEC; they provide some evidence that the redox-sensitive NF-κB 
activation is essential for TNF-α-induced microvascular endothelial cell activation in 
various human organs. 
 
Endothelial dysfunction experiments 
 
Previously, we established a young rat model of chronic NO deficiency and endothelial 
dysfunction. We examined the effects of chronic NO blockade on oxidative stress status and 
renal function in young male SD rats [159, 160]. Two types of NOS inhibitor were used: 
NG-nitro-L-arginine methyl ester (L-NAME) as a non-selective inhibitor and 
aminoguanidine as a selective inhibitor of the inducible isoform (NOS2). Oral 
administration of L-NAME, but not aminoguanidine, for 4 weeks induced systemic 
hypertension, a significant reduction in urinary nitrite/nitrate, and a significant increase in 
urinary 8-OHdG compared with non-treated animals. These rats developed proteinuria and 
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tubular enzymuria (high excretion of N-acetyl-beta-D-glucosaminidase), with normal 
serum creatinine levels. Chronic aminoguanidine administration did not significantly alter 
urinary 8-OHdG, protein, N-acetyl-beta-D-glucosaminidase, or serum creatinine. The 
effects of L-NAME on blood pressure and urinary parameters were restored by a large dose 
of L-arginine. These observations highlight the importance of continuous generation of NO 
by constitutive NOS (especially NOS3) in the control of vascular tone, renal function, and 
antioxidant capacity in young animals. 
 
Rats receiving chronic non-selective NOS inhibitor treatment exhibit various parenchymal 
lesions [161]. Enhanced oxidative stress might participate in the development of such organ 
damage in animals with chronic NO deficiency and endothelial dysfunction. 
 
Imbalance of NO/O2- formation 
 
Importantly, ROS act as signal transducers and represent a versatile cellular control 
mechanism for gene regulation [2, 149, 152]. Related to signaling of several cytokines, e.g., 
TNF-α and interleukin 1β, ROS themselves might act as an intracellular signaling system. 
Activation and DNA binding of several transcription factors depend on the cellular redox 
state. An appropriate amount of ROS generated in the cells appears to be used as a 
signaling system or as a modulating factor on signal transduction pathways from surface 
receptors. The generation of oxidants in greater quantities than the buffering capacity might 
engender excessive signals to the cells, in addition to direct damage, thereby causing cell 
death or pathological processes in which ROS are involved. 
 
As its role, NO provides cells with a reducing environment and scavenges O2- that is 
formed through metabolism. The balance between NO and O2- might be a key determinant 
in promoting oxidative stress [1, 120, 130, 131, 152-154]. Under normal physiological 
conditions, when NO is produced in greater amounts than is O2-, endogenous NO serves to 
inhibit oxidative reactions. Maximum oxidant production will occur presumably by 
 25
formation of ONOO- when fluxes of each radical are identical (the flux ratio of each radical 
is 1.0), especially in regions of low SOD activity. Endothelial activation (as represented by 
overproduction of O2- induced by TNF-α treatment [155-158]) and dysfunction (as 
represented by diminished NO synthesis [159-161]) might both produce a situation in 
which a situation of balance of NO and O2- in favor of NO is altered in favor of a more 
oxidative environment. 
 
It is noteworthy that normal function of NOS3 requires the presence of the essential 
cofactor BH4 as well as the substrate L-arginine [130, 154]. The cofactor BH4 is a potent, 
naturally occurring reducing agent; it is highly sensitive to oxidation by ONOO-. 
Diminished levels of BH4 promote O2- production by NOS3 (so-called “NOS3 
uncoupling”). This transformation of NOS3 from a protective enzyme to a contributor to 
oxidative stress has been observed in several in vitro models, in animal models of 
cardiovascular diseases, and in patients with cardiovascular risk factors [162-164]. 
 
The L-arginine-NO system might maintain a low steady state concentration of ROS that are 
being constantly formed in vivo. Furthermore, constitutively produced NO, by controlling 
the availability of ROS and the redox state of the cells, might modulate various cellular 
activities, including nuclear gene regulation. Although the results described above cannot 
be extrapolated directly to the human situation, they suggest a potential therapeutic 
approach using antioxidant agents or NO pathway modulators in the treatment of situations 
that are characterized by endothelial activation or dysfunction. 
 
(9) THERAPEUTIC IMPLICATIONS 
 
As clinicians, prevention and treatment are our ultimate interest. As described in preceding 
sections, clinical studies suggest that an imbalance between oxidant and antioxidant 
activities in favor of the former contributes to the pathogeneses of many diseases that are 
encountered in the field of pediatric medicine [15-121]. Our experimental results and those 
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of other investigators suggest that restoration of the redox balance using antioxidant agents 
might offer potential therapeutic interventions. Collectively, therapeutic interventions that 
decrease exposure to ROS or augment antioxidant defenses might be beneficial as 
adjunctive therapies for oxidative-stress related diseases. 
 
Malfunction of the NO system is implicated in numerous disease processes, resulting in 
reduced [21, 55, 64] or excessive NO production [20, 34, 39, 43, 44, 73, 85, 88, 94, 114]. 
The NOS substrates, i.e., L-arginine and BH4, can be administered to enhance NO 
production; increased NO levels can be achieved directly through administration of NO 
donors. Using NOS inhibitors, NOS activities can be decreased. The effects of NO are 
widespread. Therefore, development of therapeutic interventions is challenging. The design 
of organ-specific delivery methods as well as agents targeting specific NOS (especially 
NOS2) is necessary. Because of the short-lived nature of NO, topical treatments will 
present few systemic side effects. 
 
Antioxidant strategies, including administration of pharmacological or dietary agents are 
based on two main mechanisms: the enhancement of ROS elimination and the inhibition of 
ROS generation. The agents acting according to the former mechanism include antioxidant 
enzymes catalyzing ROS degradation and scavengers neutralizing ROS. Classic 
antioxidants include tocopherols, carotenoids, and ascorbate. It has been postulated that the 
antioxidant potency of these antioxidants may be limited because they work as scavengers 
of already-formed ROS in a stoichiometric manner. They might therefore be thought of as a 
more “symptomatic” treatment rather than as a treatment for causes of oxidative 
stress-associated clinical problems [165]. On the other hand, it has been suggested that 
angiotensin-converting enzyme inhibitors and angiotensin II type-1 receptor antagonists 
suppress intracellular overproduction of ROS and work as “causal” antioxidants and that 
many of their beneficial effects are the result of this property [165-167]. 
 
Numerous clinical trials have involved the administration of various antioxidants in the 
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pediatric field. Previously reported therapeutic antioxidant strategies include the following: 
corticosteroids for bronchial asthma [40] and bacterial meningitis [34]; L-arginine for 
endothelial dysfunction in cardiac transplantation [64]; angiotensin-converting enzyme 
inhibitors and angiotensin II type-1 receptor antagonists for endothelial dysfunction in 
diabetes mellitus [7, 95]; melatonin for neonatal asphyxia [20] and for epilepsy [76]; folinic 
acid, betaine and methylcobalamin for autism [66]; tocopherols and ubiquinol/ubiquinone 
for Friedreich ataxia [90]; selenium for skeletal muscle disorder in selenium deficiency 
[59]; tocopherols and ascorbate for endothelial dysfunction in hyperlipidemia [42]; 
glutathione and α-lipoic acid for kwashiorkor [111]; amifostine for total body irradiation 
[71] and for anticancer drug use [121]; tocopherols, carotenoids and ascorbate for 
immunosuppressive drug use (cyclosporine A, tacrolimus) [116]; and ubiquinol/ubiquinone 
for anthracycline use [117]. 
 
The authors found some favorable effects of the above antioxidant strategies. However, 
these results should be interpreted cautiously and confirmed with studies that have been 
conducted with more numerous patients and with other techniques to measure oxidative 
stress status because the studies explained in this report analyzed samples using only a few 
parameters from only a few subjects. Under certain conditions, surprisingly, the antioxidant 
supplements may exhibit prooxidant properties and even worsen tissue damage. 
Large-scale, prospective, controlled clinical trials using a multi-parameter set of oxidative 
stress biomarkers, as well as further fundamental investigations of the basic science are 
necessary to establish both the efficacy and safety of antioxidant strategies in clinical 
practice. 
 
(10) CONCLUDING REMARKS 
 
The challenges for the future are to elucidate the molecular mechanisms that engender 
oxidative stress in pediatric diseases, to develop effective therapeutic antioxidants, and to 
demonstrate their benefits to patients. However, before antioxidant therapy becomes 
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accepted in clinical practice, detailed longitudinal studies must be conducted, evaluating 
panels of oxidative stress biomarkers together with traditional clinical endpoints in patients 
who are undergoing treatment for diverse acute and chronic diseases. 
 
This review has provided current knowledge about noninvasive means of assessing 
oxidative stress status in the field of pediatric medicine. The biomarkers presented herein, 
such as acrolein-lysine, 8-OHdG, BOM, and L-FABP, can be measured easily in urine 
samples using commercially available ELISA methods. Measurement of these parameters 
will have far-reaching potential for the monitoring and treatment of oxidative-stress related 
diseases in pediatric medicine. 
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Table 1.  Oxidative stress biomarkers of two categories 
 
(a) Formation of modified molecules by reactive oxygen species 
Lipid peroxidation: malondialdehyde-lysine, 4-hydroxy-2-nonenal-lysine, acrolein-lysine*, 
F2-isoprostane 
Oxidative DNA damage: 8-hydroxy-2’-deoxyguanosine* 
Glyco-oxidation: carboxymethyl-lysine, pentosidine*, argpyrimidine, methylglyoxal 
Nitro-oxidation: nitrotyrosine, nitrite/nitrate* 
Others: o,o’-dityrosine, ortho-tyrosine, bilirubin oxidative metabolites*, dehydroascorbate, 
oxidized glutathione, “thiobarbituric acid reactive substances” 
(b) Antioxidant enzymes and molecules 
Enzymes: superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, 
glutathione-S-transferase*, thioredoxin reductase, heme oxygenase 
Proteins: albumin, ferritin, transferrin, lactoferrin, cerulolasmin, thioredoxin*, L-type fatty 
acid binding protein* 
Low molecular weight molecules: bilirubin, tocopherols, carotenoids, ubiquinol/ubiquinone, 
ascorbate, glutathione, cysteine, urate, nitrite/nitrate*, selenium 
Others: “total antioxidant reactivity”, “total radical trapping antioxidant potential” 
 
Only biomarkers that are determined in samples of blood (serum, plasma, erythrocytes, 
granulocytes or lymphocytes) or urine are shown. Nitric oxide behaves either as a 
prooxidant or as an antioxidant according to its environment. Therefore, its stable 
metabolites, nitrite/nitrate, is listed in both categories (a) and (b). *Clinical significance of 
these biomarkers is described in detail in the following sections: acrolein-lysine, 
8-hydroxy-2’-deoxyguanosine, pentosidine, nitrite/nitrate (Sections (5) and (6)), bilirubin 
oxidative metabolites (Section (6)), glutathione-S-transferase, thioredoxin, L-type fatty acid 
binding protein (Section (7)). 
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Table 2.  Possible oxidative stress involvement in pediatric diseases 
 
Allergic/Immunologic: atopic dermatitis [21*, 58*], bronchial asthma [40, 51, 74], chronic 
arthritis [15, 85], Henoch-Schonlein purpura [37], Kawasaki disease [48], systemic lupus 
erythematosus [68], vasculitis syndrome [73] 
Cardiovascular: cardiac surgery [56], cardiac transplantation [64], cardiopulmonary bypass 
[98], essential hypertension [55] 
Endocrinologic/Metabolic: diabetes mellitus [39, 63*, 95, 100, 114*], glutathione 
synthetase deficiency [33], hyperthyroidism [79], iodine-deficient goiter [26], 
mitochondrial disorder [30, 105], multimetabolic syndrome [81], phenylketonuria [91], 
X-linked adrenoleukodystrophy [69] 
Environmental/Toxicologic: carcinogenic metal (chromium, arsenic) exposure [97], ozone 
exposure [74], passive smoking [101], urban residence [89] 
Gastrointestinal/Hepatologic: autoimmune hepatitis [38], chronic constipation [112], 
inflammatory bowel disease [47], nonalcoholic fatty liver disease [75, 106], viral hepatitis 
[19], Wilson disease [78] 
Genetic: Cockayne syndrome [49], Down syndrome [54, 57], Zellweger syndrome [44] 
Hematologic: acute leukemia [52, 53, 88], β-thalassemia [45], erythropoietic 
protoporphyria [104], Fanconi anemia [72], sickle cell anemia [93] 
Infectious: acute bronchiolitis [70], acute infectious mononucleosis [48], acute otitis media 
[102], acute tonsillitis [102], adenovirus infection [48], chronic nail candidiasis [80], 
chronic otitis media [87], chronic tonsillitis [62, 82], cutaneous leishmaniasis [94], HIV 
infection [28, 99], measles encephalitis [31], meningitis [17*, 34*], septic shock [18] 
Neonatal: asphyxia [20, 41], maternal preeclampsia [77*], neonatal respiratory distress 
syndrome [86*, 96*, 108*], premature birth [27, 29, 92], retinopathy [86*, 92] 
Neurologic/Muscular: ataxia telangiectasia [23], attention deficit hyperactivity disorder 
[61], autism [43, 66, 110], cerebral organic acid disorder [35], cerebral palsy [107], 
congenital muscular dystrophy [32, 50, 60], epilepsy [30, 76, 84], Friedreich ataxia [90], 
inflammatory myopathy [60], selenium-deficient skeletal muscle disorder [59], spinal 
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muscular atrophy [24], traumatic brain injury [36, 46] 
Nutritional: hyperlipidemia [42], kwashiorkor [16, 111], obesity [83, 103] 
Pharmacologic/Therapeutic: analgesics [120], anticancer drugs [117-121], 
immunosuppressive drugs [116], total body irradiation [71] 
Renal: glomerulonephritis [109], nephrotic syndrome [25], renal insufficiency/failure [22, 
109, 113], urinary tract infection [109] 
Respiratory: chronic pulmonary disease [115], cystic fibrosis [65, 67] 
 
*The authors’ works. 
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Figure 1.  Age-related changes of urinary levels of acrolein-lysine, 
8-hydroxy-2’-deoxyguanosine (8-OHdG) and nitrite/nitrate. 
 
Data are presented as mean (SD). One-hundred healthy young people (50 males and 50 
females) are grouped into the following four groups: 1-6 years (n = 33); 6-11 years (n = 
34); 11-16 years (n = 20); 16-21 years (n = 13). Statistically significant inter-group 
difference: *p < 0.05 vs. any of the older age groups; **p < 0.05 vs. any of the older age 
groups (ANOVA using Scheffe’s method). 
 
Figure 2.  Age-related changes of urinary levels of pentosidine and pyrraline. 
 
Data are presented as mean (SD). Ninety-six healthy young people (50 males and 46 
females) are grouped into the following four groups: 1-6 years (n = 30); 6-11 years (n = 
33); 11-16 years (n = 20); 16-21 years (n = 13). Statistically significant inter-group 
difference: *p < 0.05 vs. any of the older age groups (ANOVA using Scheffe’s method). 
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